A weekly administered sustained-release growth hormone reduces visceral fat and waist circumference in abdominal obesity

Hormone and Metabolic Research

Volumn 43, Issue 13, 2011, Pages 956-961

  Hong, J W ^a   Park, J K ^a   Lim, C Y ^b   Kim, S W ^c,e   Chung, Y S ^d   Lee, E J ^a,f  

^a Yonsei University College of Medicine   (South Korea)

^b Dongguk University   (South Korea)

^c Curensia Clinic   (South Korea)

^d Ajou University School of Medicine   (South Korea)

^e Kyung Hee University Hospital   (South Korea)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

abdominal obesity; growth hormone; subcutaneous adipose tissue; visceral fat; waist circumference

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN GROWTH HORMONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SOMATOMEDIN C; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY COMPOSITION; BODY FAT DISTRIBUTION; CLINICAL ARTICLE; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; EDEMA; ERYTHEMA; FEMALE; FREE THYROXINE INDEX; HEMATOCRIT; HUMAN; HYPESTHESIA; INJECTION SITE PRURITUS; INTRAABDOMINAL FAT; LEAN BODY WEIGHT; LOW DRUG DOSE; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SUBCUTANEOUS FAT; SUSTAINED DRUG RELEASE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; WAIST CIRCUMFERENCE; WEIGHT CHANGE;

ADULT; AGED; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED; OBESITY, ABDOMINAL; PROSPECTIVE STUDIES; WAIST CIRCUMFERENCE;

EID: 83155180257     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0031-1291246     Document Type: Article

References (32)

1. Bray G A. Medical consequences of obesity. J Clin Endocrinol Metab: 2004; 89 2583 2589 (Pubitemid 38766335)
2. Phillips L K, Prins J B. The link between abdominal obesity and the metabolic syndrome. Curr Hypertension Rep: 2008; 10 156 164
3. Prez A P, Muoz J Y, Corts V B, de Pablos Velasco P. Obesity and cardiovascular disease. Public Health Nutr: 2007; 10 1156 1163 (Pubitemid 350085204)
4. Grundy S M. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation: 2002; 105 2696 2698 (Pubitemid 34615135)
5. Despres J P, Lemieux I. Abdominal obesity and metabolic syndrome. Nature: 2006; 444 881 887 (Pubitemid 46024995)
6. Albert S G, Mooradian A D. Low-dose recombinant human growth hormone as adjuvant therapy to lifestyle modifications in the management of obesity. J Clin Endocrinol Metab: 2004; 89 695 701 (Pubitemid 38269879)
7. Franco C, Brandberg J, Lonn L, Andersson B, Bengtsson B A, Johannsson G. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial. J Clin Endocrinol Metab: 2005; 90 1466 1474 (Pubitemid 40464006)
8. Gotherstrom G, Bengtsson B A, Bosaeus I, Johannsson G, Svensson J. A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. J Clin Endocrinol Metab: 2007; 92 1442 1445 (Pubitemid 46562361)
9. Hoffman A R, Biller B M, Cook D, Baptista J, Silverman B L, Dao L, Attie K M, Fielder P, Maneatis T, Lippe B. Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency. J Clin Endocrinol Metab: 2005; 90 6431 6440 (Pubitemid 41759296)
10. Johannsson G, Marin P, Lonn L, Ottosson M, Stenlof K, Bjorntorp P, Sjostrom L, Bengtsson B A. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab: 1997; 82 727 734 (Pubitemid 27106578)
11. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials. J Clin Endocrinol Metab: 2004; 89 2192 2199 (Pubitemid 38619852)
12. Carroll P V, Christ E R, Snksen P H. Growth hormone replacement in adults with growth hormone deficiency: assessment of current knowledge. Trends Endocrinol Metab: 2000; 11 231 238
13. Mekala K C, Tritos N A. Effects of recombinant human growth hormone therapy in obesity in adults: a meta analysis. J Clin Endocrinol Metab: 2009; 94 130 137
14. Nam S Y, Kim K R, Cha B S, Song Y D, Lim S K, Lee H C, Huh K B. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients. Int J Obes: 2001; 25 1101 1107 (Pubitemid 32721530)
15. Kim S J, Hahn S K, Kim M J, Kim D H, Lee Y P. Development of a novel sustained release formulation of recombinant human growth hormone using sodium hyaluronate microparticles. J Controlled Release: 2005; 104 323 335
16. Bidlingmaier M, Kim J, Savoy C, Kim M J, Ebrecht N, de la Motte S, Strasburger C J. Comparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency. J Clin Endocrinol Metab: 2006; 91 2926 2930 (Pubitemid 44271737)
17. Pasarica M, Zachwieja J J, Dejonge L, Redman S, Smith S R. Effect of growth hormone on body composition and visceral adiposity in middle-aged men with visceral obesity. J Clin Endocrinol Metab: 2007; 92 4265 4270 (Pubitemid 350074742)
18. Ahn C W, Kim C S, Nam J H, Kim H J, Nam J S, Park J S, Kang E S, Cha B S, Lim S K, Kim K R, Lee H C, Huh K B. Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese type 2 diabetic patients with poor glycaemic control. Clin Endocrinol (Oxf): 2006; 64 444 449
19. Jacobs E J, Newton C C, Wang Y, Patel A V, McCullough M L, Campbell P T, Thun M J, Gapstur S M. Waist Circumference and All-Cause Mortality in a Large US Cohort. Arch Intern Med: 2010; 170 1293 1301
20. Utz A L, Yamamoto A, Sluss P, Breu J, Miller K K. Androgens may mediate a relative preservation of IGF-I levels in overweight and obese women despite reduced growth hormone secretion. J Clin Endocrinol Metab: 2008; 93 4033 4040
21. Frystyk J, Brick D J, Gerweck A V, Utz A L, Miller K K. Bioactive insulin-like growth factor-I in obesity. J Clin Endocrinol Metab: 2009; 94 3093 3097
22. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res: 2003; 13 113 170 (Pubitemid 36986557)
23. Carel J C, Butler G. Safety of Recombinant Human Growth Hormone. Endocr Dev: 2010; 18 40 54
24. Halpern A, Mancini M C, Cercato C, Villares S M, Costa A P. Effects of growth hormone on anthropometric and metabolic parameters in android obesity. Arq Bras Endocrinol Metabol: 2006; 50 68 73 (Pubitemid 43748323)
25. Caidahl K, Edn S, Bengtsson B A. Cardiovascular and renal effects of growth hormone. Clin Endocrinol: 1994; 40 393 400 (Pubitemid 24194635)
26. Christ E R, Cummings M H, Westwood N B, Sawyer B M, Pearson T C, Snksen P H, Russell-Jones D L. The importance of growth hormone in the regulation of erythropoiesis, red cell mass, and plasma volume in adults with growth hormone deficiency. J Clinical Endocrinol Metab: 1997; 82 2985 2990 (Pubitemid 27385660)
27. Losa M, Scavini M, Gatti E, Rossini A, Madaschi S, Formenti I, Caumo A, Stidley C A, Lanzi R. Long-term effects of growth hormone replacement therapy on thyroid function in adults with growth hormone deficiency. Thyroid: 2008; 18 1249 1254
28. Porretti S, Giavoli C, Ronchi C, Lombardi G, Zaccaria M, Valle D, Arosio M, Beck-Peccoz P. Recombinant human GH replacement therapy and thyroid function in a large group of adult GH-deficient patients: when does L-T(4) therapy become mandatory? J Clinical Endocrinol Metab: 2002; 87 2042 2045 (Pubitemid 34521487)
29. Yuen K C, Dunger D B. Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults. Diabetes Obes Metab: 2007; 9 11 22 (Pubitemid 44921037)
30. Bramnert M, Segerlantz M, Laurila E, Daugaard J R, Manhem P, Groop L. Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle. J Clin Endocrinol Metab: 2003; 88 1455 1463 (Pubitemid 36623354)
31. Rizza R A, Mandarino L J, Gerich J E. Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes: 1982; 31 663 669 (Pubitemid 12095161)
32. Svensson J, Bengtsson B A. Safety aspects of GH replacement. Eur J Endocrinol: 2009; 161 01 S65 S74